In This Section

Program

Please note that this meeting will take place as an in-person event in San Diego and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the registration page for details.

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Wednesday, November 13

Thursday, November 14

Friday, November 15

Saturday, November 16

Wednesday, November 13

REGISTRATION

3-7 p.m.

WELCOME AND Keynote Lecture

6- 7:30 p.m. | Salon CDE | CME-eligible

  • 6:05 p.m. | Keynote Lecture
    Ash A. Alizadeh, Stanford University, Stanford, California
  • 6:50 p.m. | Keynote Lecture
    Revolutionizing drug development and treatment decisions through liquid biopsies
    Howard I. Scher, Memorial Sloan Kettering Cancer Center, New York, New York

OPENING RECEPTION

7:30-9 p.m.  | Grand Ballroom Foyer

Thursday, November 14

CONTINENTAL BREAKFAST

7-8 a.m.  | Hall of Fame

Plenary Session 1: Biology Behind Circulating Tumor Cells (CTCs) 

8-10:05 a.m.  | Salon CDE | CME-eligible

Session Chair: Catherine Alix-Panabières, University of Montpellier, Montpellier, France

  • 8:05 a.m. | The biology of metastasis-competent CTCs in colon and breast cancer
    Catherine Alix-Panabières
  • 8:35 a.m. | Early cancer dissemination: Circulating tumor cells in ductal carcinoma in situ patients
    Sunitha Nagrath, University of Michigan, Ann Arbor, Michigan
  • 9:05 a.m. | Tumor cell-based liquid biopsy to characterize prostate cancer
    Daniel A. Haber, Massachusetts General Hospital, Boston, Massachusetts
  • 9:35 a.m. | The CTC signature of melanoma brain metastasis*
    Dario Marchetti, The University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico
  • 9:50 a.m.| The clinical relevance of circulating tumor cell size in head and neck squamous cell carcinoma patients*
    Hyeongjung Woo, Department of New Biology, DGIST, Daegu Republic of Korea   

Break

10:05-10:25 a.m.  | Grand Ballroom Foyer

Plenary Session 2: Biology of Plasma Biomarkers 

10:25-12:30 p.m. | Salon CDE | CME-eligible

Session Chair: David C. Lyden, Weill Cornell Medicine, New York, New York

  • 10:30 A.M. | The biology of extracellular vesicles
    David C. Lyden
  • 11 a.m. | Modulating cfDNA biology to enhance liquid biopsies
    Viktor Adalsteinsson, Broad Institute of MIT and Harvard, Cambridge, Massachusetts
  • 11:30 a.m. | The biology of non-coding RNAs: From basic science to patients 
    George A. Calin, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 12 p.m. | ctDNA release kinetics and fragmentation to monitor treatment response and resistance in esophageal adenocarcinoma*
    Alexandra Bartolomucci, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
  • 12:15 p.m. | Biological insights into tissue-agnostic plasma cfDNA methylation signature for surveillance of head and neck tumor recurrence*
    Yulia Newton, Adela, Inc., Foster City, California

Lunch on Own / Free Time

12:30-2:45 p.m.

Plenary Session 3: New Technologies for Liquid Biopsy Analyses 

2:45-5:05 p.m. | Salon CDE | CME-eligible

Session Chair: Maximilian Diehn, Stanford University, Stanford, California

  • 2:50 p.m. | Ultra-sensitive ctDNA technologies
    Maximilian Diehn
  • 3:25 p.m. | Heterogeneity of cancer-derived extracellular vesicles 
    Dolores Di Vizio, Cedars-Sinai Medical Center, Los Angeles, California
  • 4 p.m. | Circulating proteins
    Samir M. Hanash, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 4:35 p.m. | Leveraging mass cytometry for phenotyping CTCs in SCLC liquid biopsies: Tracking therapy resistance at a personalized level*
    Loukia G. Karacosta, MD Anderson Cancer Center, Houston, Texas

Poster Session A / Reception 

5:15-7:15 p.m.  | Salon AB

Evening off/ Dinner on Own

7:15 p.m.

Friday, November 15

CONTINENTAL BREAKFAST

7-8 a.m.  | Hall of Fame

Plenary Session 4: Early Detection of Primary Cancer and Relapse

8-10:05 a.m. | Salon CDE | CME-eligible

Session Chair: Nickolas Papadopoulos, Johns Hopkins Medicine, Baltimore, Maryland

  • 8:05 a.m. | Leveraging multiomics and machine learning towards a stepwise approach to multi-cancer screening
    Jimmy Lin, Freenome, Inc., South San Francisco, California
  • 8:35 a.m. | Early detection and cancer screening
    Lori Minasian, National Cancer Institute, Bethesda, Maryland
  • 9:05 a.m | The CancerSEEK studies
    Nickolas Papadopoulos
  • 9:35 a.m. | The potential of multi-cancer early detection screening for reducing cancer mortality*
    Chris Tyson, Exact Sciences Corporation, Madison, Wisconsin
  • 9:50 a.m. | Screening early detection of HPV-associated oropharynx cancers with multi-feature HPV whole genome sequencing liquid biopsy*
    Daniel L. Faden, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

BreaK

10:05-10:25 a.m. | Grand Ballroom Foyer

Plenary Session 5: Liquid Biopsy Detection and Monitoring of MRD 

10:25 a.m.- 12:15 p.m.  | Salon CDE | CME-eligible

Session Chair: Jeanne Tie, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 

  • 10:30 a.m. | Early detection of MRD in cancer patients
    Klaus Pantel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 
  • 11 a.m. | ctDNA based detection of MRD in colorectal cancer: Towards clinical implementation
    Jeanne Tie
  • 11:30 a.m. | Liquid biopsy in head and neck cancers: A model for tissue-agnostic MRD detection
    Scott V. Bratman, University of Toronto, Toronto, ON, Canada 
  • 12 p.m. | Genome-wide analyses of cfDNA fragmentomes for therapeutic monitoring of patients with pancreatic cancer*
    Carolyn A. Hruban, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland

Lunch on Own/ Free Time

12:15-2:30 p.m.

Plenary Session 6: Monitoring Tumor Evolution in Cancer Patients 

2:30-4:35 p.m. | Salon CDE | CME-eligible

Session Chair: Klaus Pantel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • 2:35 p.m. | Cell-free DNA fragmentomics for cancer detection and monitoring 
    Jillian A. Phallen, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 3:05 p.m.
    Jacqui A. Shaw, University of Leicester, Leicester, England
  • 3:35 p.m. |AI-guided SNV detection for monitoring tumor fraction and somatic mutations
    Adam Widman, Memorial Sloan Kettering Cancer Center, New York, New York
  • 4:05 p.m. | Application of Liquid Biopsy-RECIST (LB-RECIST) criteria to track metastatic colorectal cancer (mCRC) molecular response in first-line (1L) setting: findings from the PLATFORM-B study*
    Valentino Martelli, Hospital del Mar Research Institute, Barcelona, Spain
  • 4:20 p.m. | High purity CTC RNA sequencing identifies poor prognosis lineage states in castrate resistant prostate cancer*
    Marina N. Sharifi, University of Wisconsin-Madison, Madison, Wisconsin

Special Session: Proffered Talks from Highly-Rated Abstracts

4:45-6:15 p.m. | Salon CDE | CME-eligible

Session Chair: Jillian A. Phallen, Johns Hopkins University School of Medicine, Baltimore, Maryland

  • 4:45 p.m. | Advance prostate cancer detection through epigenomic profiling of cell-free DNA*
    Mohamed Adil, University of Washington, Seattle, Washington
  • 5 p.m. | Comprehensive epigenomic profiling from plasma to inform drug development, cancer biology, and therapy selection*
    Carl Barrett, Precede Biosciences, Boston, Massachusetts
  • 5:15 p.m. | Highly accurate detection of early-stage colorectal cancer using tumor and immune extracellular vesicles biomarkers*
    Todd Hembrough, Nexosome Oncology, Durham, North Carolina
  • 5:30 p.m. | Robust disease monitoring using CSF liquid biopsies collected from children undergoing cellular therapy for malignant central nervous system tumors*
    Anna Kostecka, St. Jude Children’s Research Hospital, Memphis, Tennessee
  • 5:45 p.m. | Novel digital PCR ctDNA monitoring assay evaluating exceptional responders to combination immune-oncology (IO) therapy*
    Daniel Stetson, AstraZeneca, Waltham, Massachusetts
  • 6 p.m. | Chromatin landscapes and cell-free DNA fragmentation in colorectal cancer development*
    Nicholas A. Vulpescu, Johns Hopkins University School of Medicine, Baltimore, Maryland

Poster Session B/ Reception

6:15- 8:15 p.m. | Salon AB

Evening off/ Dinner on Own

8:15 p.m.

Saturday , November 16

CONTINENTAL BREAKFAST

7-8 a.m. . | Hall of Fame

Plenary Session 7: Liquid Biopsy and Immunotherapy

8-10:05 a.m. | Salon CDE | CME-eligible

Session Chair: Luis A. Diaz, Jr., Memorial Sloan Kettering Cancer Center, New York, New York

  • 8:05 a.m. | Fragmentomic features of cell-free DNA predict late-stage melanoma treatment benefit and survival
    Aaron B. Beasley, Edith Cowan University, Joondalup, Australia
  • 8:35 a.m.
    Luis A. Diaz, Jr., Memorial Sloan Kettering Cancer Center, New York, New York
  • 9:05 a.m. | Validation of liquid biopsy approaches for the care of children with cancer
    Brian D. Crompton, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 9:35 a.m. | A T-cell signature in circulating cell-free DNA at time of diagnosis predicts response to checkpoint inhibition*
    Benjamin Schuster-Boeckler, Ludwig Cancer Research, University of Oxford, Oxford, United Kingdom
  • 9:50 a.m. | Plasma proteomic biomarkers reveal biological insights about the tumor microenvironment in melanoma patients after PD1 blockade*
    Samuel J. Wright, Broad Institute of MIT and Harvard, Cambridge, Massachusetts

BREAK

10:05-10:25 a.m.  | Grand Ballroom Foyer

Plenary Session 8: Computational Science in Liquid Biopsy Analyses

10:25 a.m.- 12:30 p.m. | Salon CDE | CME-eligible

Session Chair: Núria Malats Riera, Spanish National Cancer Research Centre (CNIO), Madrid, Spain  

  • 10:30 a.m. | A DNA methylation atlas of normal human cell types
    Tommy Kaplan, The Hebrew University of Jerusalem, Jerusalem, Israel
  • 11 a.m. | Methods for tumor subtype classification using cell-free DNA
    Gavin Ha, Fred Hutchinson Cancer Center, Seattle, Washington
  • 11:30 a.m. | Multimodal-data integration
    Núria Malats Riera
  • 12 p.m. | Transfer learning for accurate tissue of origin classification from cfDNA methylation*
    Shiva Farashahi, Harbinger Health, Cambridge, Massachusetts
  • 12:15 p.m. | A novel framework for epigenome-dependent multimodal fragment-signature analysis reveals insights into cell-free DNA generation in cancer*
    Yoo-Na Kim, Harvard Medical School, Boston, Massachusetts

Closing Comments / Departure

12:30 p.m. | Salon CDE